News Release
Oxford Cannabinoid Technologies CEO says objective "absolutely met" in lead asset trial
Oxford Cannabinoid Technologies Holdings PLC
Oxford Cannabinoid Technologies Holdings PLC (LSE:OCTP, OTCQB:OCTHF) chief executive Clarissa Sowemimo-Coker speaks to Thomas Warner from Proactive London after the pharmaceutical group announced phase 1 clinical trial results for its lead drug candidate OCT461201. Sowemimo-Coker explains that OCT461201 is the most advanced of the company's four programmes. The trial, conducted in collaboration with Simbec-Orion, tested the compound on healthy volunteers, with the final dose administered on September 20th. She says "since then we've been crunching the numbers and just processing those healthy volunteers to make sure we are in good shape and I'm very pleased to report [that we're] absolutely fine, no adverse events and all looking good from a safety and tolerability point of view - so that objective absolutely met." Sowemimo-Coker emphasises that while the compound binds to a cannabinoid receptor, it's technically not a cannabinoid but a new chemical entity. The company aims to treat chemotherapy-induced peripheral neuropathy (CIPN) with this compound, a condition affecting 60% of chemotherapy patients. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com
October 10, 2023 04:36 AM Eastern Daylight Time
Video
News Release
Chill Brands Group makes major breakthrough with WHSmith agreement
Chill Brands Group PLC
Chill Brands Group PLC (LSE:CHLL, OTCQB:CHBRF) CEO Callum Sommerton speaks to Thomas Warner from Proactive after the wellness and recreational products company announced it has secured a deal with major UK retailer WHSmith to stock Chill Brands' nicotine-free Chill Zero vape products. The products will be available in 150 of WH Smith's travel stores, including airport and train station locations. These hubs offer high exposure, reaching thousands of daily travellers. Sommerton emphasises that the nicotine-free vape products target individuals aged 18-35, offering a healthier alternative to nicotine products. Despite a 10-12% bump in share price following the announcement, Sommerton acknowledges challenges in the market, including geopolitical issues and concerns around vaping. However, he remains optimistic about the industry's adaptability to regulations and reaffirms Chill Brands' commitment to ethical retailing. Additionally, he hinted at expanding the chill.com platform, introducing new brands and product categories, including wellness items and hemp products. He says that "as we continue to grow the channel and add additional retailers off the back of this announcement, I think people will understand that we are here to stay." Contact Details UK Editorial +44 20 7989 0813 uk@proactiveinvestors.com
October 10, 2023 04:27 AM Eastern Daylight Time
Video
News Release
CORRECT AND REPLACE: Valeo Pharma CEO credits Enerzair for strong position on Canada’s top-growing companies list
Valeo Pharma Inc.
Valeo Pharma Inc. (TSX:VPH, OTCQB:VPHIF) CEO Steve Saviuk joined Proactive's Stephen Gunnion to discuss the company's strong position on the Globe and Mail's Report on Business annual list of Canada’s top-growing companies. The company placed 151 out of 425, with a three-year growth rate of 322%. Saviuk explained that the rankings are calculated on revenue growth, and the exponential growth in the company's Enerzair asthma therapy helped it secure its position. Despite launching less than two years ago, he said Enerzair and Atectura account for one out of every five new prescriptions. Given the current trajectory, Saviuk said the company may rank even higher in 2024. The Report on Business magazine launched Canada’s Top Growing Companies ranking in 2019 and companies have to complete an in-depth application process and fulfill certain requirements in order to be recognized. Valeo Pharma is a fast-growing Canadian pharmaceutical company dedicated to the commercialization of innovative prescription products in Canada with a focus on Respiratory/Allergy, Ophthalmology and Hospital Specialty Products. Contact Details Proactive +1 604-688-8158 na-editorial@proactiveinvestors.com
October 07, 2023 03:45 AM Eastern Daylight Time
Video
News Release
Nevis Brands announces partnership with Blaze Life to launch Major brand in California
Nevis Brands
Nevis Brands Inc CEO John Kueber joined Proactive's Stephen Gunnion with details of a new partnership with Blaze Life Holdings to produce and distribute the company's major cannabis beverage brands in California. Nevis Brands owns industry-leading cannabis beverage brands and operates by partnering with licensees in different states due to the state-specific regulations in the US cannabis market. These partners use their infrastructure to produce and sell Nevis Brands' products, with Nevis Brands collecting royalties on sales. Blaze Life Holdings, a leader in the California Cannabis Industry, is building a state-of-the-art facility in Los Angeles to facilitate the production and distribution of Nevis Brands' 100 milligram THC beverage, Major. California's cannabis market is one of the largest globally, and Kueber said Blaze Life's expertise in the beverage industry and California distribution makes it an ideal partner. The launch of Major in California is expected before the end of the year, with compliance and production setup underway. Nevis Brands plans to expand to other states, and while they have a bias to work with existing partners, they remain open to new collaborations in their pipeline of growth opportunities. Contact Details Proactive Canada +1 604-688-8158 na-editorial@proactiveinvestors.com
October 06, 2023 01:07 PM Eastern Daylight Time
Video
News Release
BiVictriX Therapeutics appoints combined CFO/CBO to boost out-licensing efforts
BiVictriX Therapeutics PLC
BiVictriX Therapeutics PLC (AIM:BVX, OTC:BVTXF) incoming chief financial officer Adrian Howd speaks to Thomas Warner from Proactive London about what he hopes to achieve in the new role, which is being combined with the newly-created position of chief business officer. Howd introduces himself, highlighting his 20+ years in the biotech sector and the roles he's played in several emerging biotech companies and investment ventures. At BiVictriX, he will lead negotiations with larger companies interested in their evolving products. Howd expresses his confidence in the potential of BiVictriX's product pipeline and its lead asset BVX001 in particular, saying that its "a molecule that looks really different to other products... the antibody drug conjugate space is fairly new... but its the fastest growing element of new cancer therapy." Despite challenges in the broader biotech sector, Howd expressed confidence in BiVictriX's future, praising its scientific approach and the achievement of the team so far. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com
October 06, 2023 03:00 AM Eastern Daylight Time
Video
News Release
Safe Supply Streaming Co now trading on the Canadian Securities Exchange with ticker SPLY
Safe Supply Streaming Co Ltd
Safe Supply Streaming Co CEO Bill Panagiotakopoulos and advisor Ronan Levy joined Steve Darling from Proactive to share news that the company has commenced trading on the Canadian Securities Exchange under the ticker symbol 'SPLY.' The company, with its strong financial footing, is strategically aligned with pivotal drug policy reform movements around the world. Panagiotakopoulos explained that Safe Supply Streaming is a pioneering company that invests in the legal and regulated supply of drugs that were traditionally only accessible through illicit markets. The company is actively deploying capital to address the ongoing fentanyl crisis and emerging opportunities related to the coca plant. Levy says the company's focus is on investing in and incubating businesses throughout the safe supply value chain. This includes companies that offer products, solutions, and technologies to combat the physical, financial, and emotional damage caused by drug abuse. Safe Supply Streaming Co's commitment to drug policy reform and harm reduction positions it at the forefront of a critical global issue. Contact Details Proactive Investors +1 604-688-8158 na-editorial@proactiveinvestors.com
October 05, 2023 01:30 PM Eastern Daylight Time
Video
News Release
1606 announces launch of revolutionary AI chatbot to enhance customer experiences is expected soon
1606 Corp.
1606 Corp CEO Greg Lambrecht joined Steve Darling from Proactive to share news that the company’s new AI chatbot ChatCBD, which is designed to revolutionize the customer experience will soon be live. Lambrecht explained that ChatCBD, developed in partnership with Cool Blue Distribution, is a comprehensive and custom-tailored tool that aims to respond to customer inquiries related to CBD and provide product recommendations from a range of retail brands available through Cool Blue Distribution, a prominent CBD distributor in the United States. What sets ChatCBD apart is its incorporation of Natural Language Processing technology, which enables it to respond to customer queries with a remarkable degree of precision and understanding, akin to human interactions. The chatbot operates 24/7, ensuring that customers receive prompt assistance and solutions to their questions, even outside regular business hours. This innovative approach not only enhances the customer experience but also showcases 1606 Corp's commitment to leveraging cutting-edge technology to provide valuable solutions in the growing CBD market. By offering an AI-driven chatbot for CBD-related inquiries and product recommendations, 1606 Corp aims to create a seamless and informative shopping experience for consumers exploring the world of CBD products. This initiative underscores the company's dedication to staying at the forefront of the CBD industry. Contact Details Proactive Canada +1 604-688-8158 na-editorial@proactiveinvestors.com
October 05, 2023 12:10 PM Eastern Daylight Time
Video
News Release
Addex Therapeutics focused on securing new partnerships to fund promising treatments
Addex Therapeutics Ltd
Addex Therapeutics co-founder and CEO Tim Dyer speaks to Thomas Warner from Proactive about the work that the central nervous system-focused clinical-stage pharmaceutical company has been doing in the promising area of allosteric modulation. He explains that company is currently collaborating with Johnson & Johnson on a phase two study for epilepsy, with results expected in Q2 of the following year. Additionally, Addex is developing treatments for chronic cough, schizophrenia, and cognition, with the latter receiving a grant from the European Union. Dyer explains that the company's unique approach to allosteric modulation offers a competitive edge in drug discovery, setting them apart from competitors. Their long-term strategy revolves around advancing their programs and securing partnerships to ensure steady cash inflows, especially given the challenging capital market environment. With seven programs in the pipeline and two already partnered, Addex is poised for significant growth in the coming years. Dyer says that "at the moment we continue to move the programs forward... we're very focused today on securing cash inflows to keep the business going through partnerships." Contact Details Proactive United States Proactive United States +1 347-449-0879 action@proactiveinvestors.com
October 05, 2023 11:20 AM Eastern Daylight Time
Video
News Release
Shield Therapeutics' pricing will be "key metric" - Proactive Research Analyst
Shield Therapeutics PLC
Proactive Research Analyst Robin Davison speaks to Thomas Warner after publishing a new research note on iron defiency-focused commercial-stage specialty pharmaceutical company Shield Therapeutics. Davison gives an overview of what readers can expect from the note, highlighting Shield's recent half-year results and accompanying financing transactions. The company's burgeoning relationship with commercial partner Viatris is a key focus. While the product's trajectory is promising, Davison explains that Shield has been grappling with the challenge of drug reimbursements in the US, leading to the incurring of some costs. However, plans are underway to assist doctors in navigating this system, with a view to securing a higher average drug price. Davison suggests that Shield's ability to increase that average price will be a "key metric going forward." He concludes by saying that "the trajectory is going extremely well, [they' really just want to get the pricing issue sorted now and it should be a great story." Davison's research note is available on the Proactive website as is a interview with Shield Therapeutics' CEO Greg Madison. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com
October 05, 2023 04:00 AM Eastern Daylight Time
Video
